×

Voyager Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that company management will present at the following upcoming investor conferences in New York City:

  • Piper Jaffray GenomeRx Symposium
    Date: Tuesday, May 17, 2016
    Panel 1 Title: Thinking Smart About CNS Targeting Gene Therapy
    Time: 11:20 a.m. ET
    Panel 2 Title: Manufacturing, Automating, Scaling Up
    Time: 2:15 p.m. ET
  • 2016 UBS Global Healthcare Conference
    Date: Monday, May 23, 2016
    Time: 8:30 a.m. ET
  • Jefferies 2016 Global Healthcare Conference
    Date: Tuesday, June 7, 2016
    Time: 8:30 a.m. ET

Live-streaming webcasts of company presentations at the UBS and Jefferies Global Healthcare Conferences can be accessed through the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. Webcasts will be archived for 30 days after the live events conclude.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.

Investor Relations & Media Contact: Matt Osborne Head of Investor Relations & Corporate Communications 857-259-5353 mosborne@vygr.com

Source:Voyager Therapeutics